The US Departments of Health and Human Services, Agriculture, Commerce, Homeland Security, Transportation, as well as the Consumer Product Safety Commission, the Environmental Protection Agency and the US Trade Representative have issued draft guidance on Good Importer Practices, to ensure that imported products are in compliance with the relevant US laws and regulations.
Jeffrey Shuren, Associate Commissioner for policy and planning at the Food and Drug Administration, said: "this draft guidance provides importers with recommendations to assist them in preventing or detecting potential problems at critical points along the product's life cycle." Over the past couple of years, the FDA has had to cope with contaminated medicines and food products, including counterfeit supplies of the blood-thinner heparin, melamine-adulterated dairy products and pet food and diethylene glycol in cough remedies and toothpaste (Marketletters passim).
In a statement, the FDA listed the four guiding principles under which the draft GIPs are organized: establishing a product safety management program; knowing the product and applicable US requirements; verification and company compliance with US rules throughout the supply chain and product cycle; and taking corrective and preventative action if the imported product fails to meet US standards.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze